Loading
Federal Rules of Civil Procedure
12 min read
Published Date:
Last Modified Date:
Federal Rule of Civil Procedure 16.1 provides a framework for managing multidistrict litigation and can shape how courts and parties coordinate expert discovery, common scientific issues, admissibility challenges, and case-specific analysis. This article explains how Rule 16.1 interacts with Rules 26, 37, and Federal Rule of Evidence 702, including expert disclosures, leadership coordination, bellwether proceedings, and the distinction between shared and individualized expert evidence.
Federal Rule of Civil Procedure 16.1 provides a framework for the early management of federal multidistrict litigation (MDL). Effective December 1, 2025, the rule addresses initial management conferences, party reporting, leadership counsel, discovery planning, and pretrial coordination.
The Supreme Court directed that the rule apply to civil proceedings commenced on or after December 1, 2025, and, insofar as just and practicable, to proceedings then pending.
Although Rule 16.1 does not establish new expert-witness requirements, its procedures can influence how parties organize expert discovery, address common scientific questions, and prepare admissibility challenges.
In pharmaceutical, product liability, environmental, and other complex litigation, multiple actions may involve overlapping technical evidence. Attorneys should assess which issues may be examined collectively and which call for individualized expert analysis.
This guide explains how Rule 16.1 affects expert evidence management, how it interacts with existing federal discovery and evidence rules, and what attorneys should consider when coordinating expert-related proceedings.
Rule 16.1 establishes an initial management process for actions transferred under 28 U.S.C. § 1407. Under that statute, the Judicial Panel on Multidistrict Litigation may transfer civil actions pending in different federal districts when they share common factual questions. The transfer must also serve the convenience of parties and witnesses and promote the just and efficient conduct of the actions.
After transfer, the transferee court should schedule an initial management conference to develop a preliminary plan for orderly pretrial proceedings.
The conference allows the parties and court to identify important issues early, although the Committee Notes clarify that a conference is not mandatory in every MDL.
The transferee court should direct the parties to meet and submit a report before the initial conference.
A court-ordered report must cover the matters the court identifies and, unless the court orders otherwise, the subjects listed in Rule 16.1(b)(2) and (3).
Among other subjects, the report covers the parties' views on leadership counsel, existing scheduling orders, future management conferences, direct filing, and coordination with related proceedings. It also addresses initial views on discovery, information exchange, likely pretrial motions, and principal factual and legal issues.
When an initial management conference is held, Rule 16.1(c) provides that the transferee court should enter an initial management order addressing the matters identified in Rule 16.1(b) and any additional matters the court considers appropriate.
The initial management order controls the course of proceedings unless modified. The court may revise the order or issue additional orders as the MDL progresses.
Federal Rule of Civil Procedure 16.1 provides a framework for the early management of federal multidistrict litigation (MDL). Effective December 1, 2025, the rule addresses initial management conferences, party reporting, leadership counsel, discovery planning, and pretrial coordination.
The Supreme Court directed that the rule apply to civil proceedings commenced on or after December 1, 2025, and, insofar as just and practicable, to proceedings then pending.
Although Rule 16.1 does not establish new expert-witness requirements, its procedures can influence how parties organize expert discovery, address common scientific questions, and prepare admissibility challenges.
In pharmaceutical, product liability, environmental, and other complex litigation, multiple actions may involve overlapping technical evidence. Attorneys should assess which issues may be examined collectively and which call for individualized expert analysis.
This guide explains how Rule 16.1 affects expert evidence management, how it interacts with existing federal discovery and evidence rules, and what attorneys should consider when coordinating expert-related proceedings.
Rule 16.1 establishes an initial management process for actions transferred under 28 U.S.C. § 1407. Under that statute, the Judicial Panel on Multidistrict Litigation may transfer civil actions pending in different federal districts when they share common factual questions. The transfer must also serve the convenience of parties and witnesses and promote the just and efficient conduct of the actions.
After transfer, the transferee court should schedule an initial management conference to develop a preliminary plan for orderly pretrial proceedings.
The conference allows the parties and court to identify important issues early, although the Committee Notes clarify that a conference is not mandatory in every MDL.
The transferee court should direct the parties to meet and submit a report before the initial conference.
A court-ordered report must cover the matters the court identifies and, unless the court orders otherwise, the subjects listed in Rule 16.1(b)(2) and (3).
Among other subjects, the report covers the parties' views on leadership counsel, existing scheduling orders, future management conferences, direct filing, and coordination with related proceedings. It also addresses initial views on discovery, information exchange, likely pretrial motions, and principal factual and legal issues.
When an initial management conference is held, Rule 16.1(c) provides that the transferee court should enter an initial management order addressing the matters identified in Rule 16.1(b) and any additional matters the court considers appropriate.
The initial management order controls the course of proceedings unless modified. The court may revise the order or issue additional orders as the MDL progresses.
Rule 16.1(b)(2)(A) addresses whether leadership counsel should be appointed and, if so, how leadership should be structured. Appointment is not mandatory in every MDL.
When appointed, leadership counsel may coordinate common discovery and other pretrial activities within the authority granted by court orders. Responsibilities may include organizing scientific document production, expert depositions, and proposals for common evidentiary proceedings.
The Committee Notes emphasize communication with nonleadership counsel and opportunities for those attorneys to express their views to the court. Coordination must also account for counsel's continuing responsibilities to their clients.
Rule 16.1 supports early discussion of common factual issues, discovery difficulties, and significant pretrial motions without establishing separate expert-discovery requirements.
Rule 16.1(b)(3)(G) calls for the parties' initial views on the principal factual and legal issues likely to arise.
In litigation involving specialized evidence, these issues may include:
Pharmaceutical litigation: Clinical studies, epidemiological evidence, pharmacological mechanisms, and general causation.
Product liability litigation: Common product designs, manufacturing records, testing procedures, and alleged failure mechanisms.
Environmental litigation: Contaminant characteristics, sampling data, exposure pathways, and potential health risks.
Medical device litigation: Device design, engineering evaluations, clinical evidence, and reported complications.
Qualified experts may review relevant records, assess scientific methods, conduct appropriate testing, or explain technical findings.
The appropriate scope of analysis depends on the claims, defenses, and available evidence.
Rule 16.1(b)(3)(C) identifies discovery, including anticipated difficulties, as a subject for the parties' initial report.
A transferee court may use this information to develop discovery procedures suited to the litigation.
Depending on the circumstances, expert-related discovery may involve:
Coordinated production of scientific datasets and technical records.
Procedures for inspecting products or testing physical evidence.
Scheduling expert reports, depositions, and related discovery.
Sequencing discovery concerning common and individual issues.
Addressing confidentiality, privilege, and proportionality concerns.
These measures are discretionary, not required in every MDL.
In an MDL, expert evidence may address issues shared across multiple actions, but coordinated discovery does not eliminate the need for case-specific analysis.
In litigation involving an allegedly harmful pharmaceutical product, epidemiologists, pharmacologists, or toxicologists may evaluate whether the available scientific evidence supports an opinion that exposure to the product, under conditions relevant to the claims, is capable of causing a particular injury or condition.
This analysis concerns general causation. Depending on the substance and alleged injury, relevant considerations may include exposure levels, duration, and the available scientific evidence. Whether the exposure actually caused a particular claimant's injury is a separate question of specific causation.
In product liability litigation, common expert analysis might instead examine design specifications, materials, manufacturing processes, or alleged failure mechanisms.
Case-specific analysis addresses facts relevant to an individual action.
Depending on the dispute, a qualified expert may evaluate:
Individual exposure history and estimated exposure levels.
Medical records and diagnostic findings.
Alternative explanations for an alleged injury.
The circumstances surrounding a particular product failure.
Individual economic losses or other damages requiring specialized assessment.
Evidence that a substance can cause a particular condition does not, by itself, establish that it caused an individual claimant's condition.
The expert's methodology must fit the question being examined and the available facts.
Expert disclosures in federal MDL proceedings remain governed by Rule 26 and applicable court orders, not by separate disclosure requirements under Rule 16.1.
Under Rule 26(a)(2), parties generally must identify witnesses they may use at trial to present expert testimony.
Unless otherwise stipulated or ordered, Rule 26(a)(2)(B) requires a written report prepared and signed by each expert retained or specially employed to provide expert testimony and each employee whose duties regularly involve giving expert testimony.
The report must contain:
A complete statement of the expert's opinions and their bases and reasons.
The facts or data considered in forming those opinions.
Exhibits used to summarize or support the opinions.
The expert's qualifications, including publications authored during the preceding 10 years.
A list of cases in which the expert testified at trial or by deposition during the preceding four years.
A statement of compensation for the study and testimony.
Unless otherwise stipulated or ordered, Rule 26(a)(2)(C) requires summary disclosures for witnesses identified under Rule 26(a)(2)(A) who are not required to provide written reports.
Rule 26(a)(2)(D) requires expert disclosures at the times and in the sequence ordered by the court, with default deadlines applying when no relevant stipulation or court order controls.
In an MDL, the court may establish separate schedules for common and individualized expert work, including general-causation discovery before certain case-specific discovery when appropriate.
Rule 26(b)(4)(B) protects drafts of reports and disclosures required under Rule 26(a)(2), regardless of their recorded form.
Rule 26(b)(4)(C) generally protects communications between a party's attorney and an expert required to provide a written report. Exceptions apply to communications concerning expert compensation, facts or data provided by counsel that the expert considered, and assumptions provided by counsel that the expert relied on in forming an opinion.
Under Rule 26(b)(4)(D), discovery of facts known or opinions held by certain experts retained solely for trial preparation and not expected to testify is generally restricted, subject to specified exceptions, including a showing of exceptional circumstances.
Federal Rule of Evidence 702 continues to govern expert testimony admissibility in federal MDL proceedings. Rule 16.1 does not create a different standard.
Separately, Rule 16(c)(2)(C) and (D) allow courts to address evidentiary admissibility and limits on expert testimony during pretrial management.
Under Rule 702, the proponent must show that it is more likely than not that the rule's requirements are met.
When expert testimony is challenged, the court considers whether:
The expert is qualified by knowledge, skill, experience, training, or education.
The expert's specialized knowledge will assist the trier of fact.
The testimony is based on sufficient facts or data.
The testimony results from reliable principles and methods.
The opinion reflects a reliable application of those principles and methods to the facts of the case.
The 2023 amendment to Rule 702 clarified the applicable burden and emphasized the court's responsibility to evaluate the reliability of the expert's methodology and its application.
Rule 16.1(b)(3)(D) identifies likely pretrial motions as a subject for the parties' initial report.
When multiple actions share a scientific question, the transferee court may coordinate briefing or discovery related to Rule 702 challenges, such as disputes over an epidemiological expert's general-causation methodology.
Other challenges may depend on an expert's analysis of an individual claimant's circumstances.
Coordinated proceedings do not make an opinion automatically admissible in every related case. Courts must still apply Rule 702 to the testimony offered.
In Engilis v. Monsanto Co., 151 F.4th 1040 (9th Cir. 2025), an appeal arising from the Roundup MDL, the Ninth Circuit affirmed the exclusion of a specific-causation opinion based on an unreliable differential-etiology analysis. The expert had failed to provide a sufficiently reliable basis for ruling out obesity as a potential cause of the plaintiff's cancer.
The decision illustrates that case-specific causation opinions remain subject to Rule 702's reliability requirements even when the underlying litigation involves shared scientific issues.
Bellwether proceedings may help parties and courts evaluate recurring issues through selected actions, but Rule 16.1 does not require bellwether trials.
Bellwether trials must comply with applicable jurisdictional and procedural requirements. These include limits on a transferee court's authority to try cases transferred under 28 U.S.C. § 1407.
In Lexecon Inc. v. Milberg Weiss Bershad Hynes & Lerach, 523 U.S. 26 (1998), the Supreme Court held that an MDL transferee court could not use 28 U.S.C. § 1404(a) to assign a transferred action to itself for trial.
Under 28 U.S.C. § 1407(a), transferred actions that have not been terminated generally must be remanded by the Judicial Panel on Multidistrict Litigation to their originating districts at or before the conclusion of coordinated pretrial proceedings.
A valid waiver of an applicable Lexecon objection may permit a transferred action to be tried in the transferee district. Directly filed actions raise separate jurisdictional and venue considerations that depend on the circumstances and applicable orders.
In In re DePuy Orthopaedics, Inc., 870 F.3d 345 (5th Cir. 2017), a majority of the Fifth Circuit panel concluded that the MDL court erred in finding a broad waiver of the defendants' Lexecon objections. A different majority nevertheless denied the petition for a writ of mandamus because the petitioners had not established that they lacked another adequate means of obtaining relief.
Attorneys planning bellwether trials should therefore examine the filing or transfer history of the selected actions, applicable venue requirements, the scope of any waiver, and relevant case management orders.
The Rule 16.1 Committee Notes identify bellwether trials as one activity leadership counsel may help coordinate.
In selected cases, a product engineering expert may examine a shared design issue while another expert evaluates evidence concerning an individual claimant's alleged injury.
Findings in selected bellwether cases do not automatically determine the outcomes of other actions. Any broader legal effect depends on the applicable law and procedural circumstances.
Attorneys preparing for Rule 16.1 proceedings should focus on several practical considerations:
Identify common and individual issues: Distinguish shared technical questions from matters requiring case-specific analysis.
Assess evidence availability: Identify relevant scientific records, technical documents, testing materials, and preservation needs.
Evaluate expert methodologies: Consider the relevant professional disciplines, analytical methods, and potential admissibility disputes.
Plan discovery sequences: Determine whether experts need information from earlier discovery, consistent with Rule 26 and applicable court orders.
Monitor compliance: Track disclosure, supplementation, and discovery deadlines as MDL orders evolve.
Under Rule 37(c)(1), a party that fails to disclose information or identify a witness as required by Rule 26(a) or 26(e) generally cannot use that information or witness on a motion, at a hearing, or at trial unless the failure was substantially justified or harmless.
On motion and after an opportunity to be heard, the court may also impose specified sanctions instead of or in addition to exclusion, including reasonable expenses and attorney's fees caused by the failure.
Federal Rule of Civil Procedure 16.1 provides a flexible framework for early MDL management. Its procedures can help courts and parties identify common disputes, plan discovery, and coordinate expert-related pretrial activities.
Effective expert evidence management requires distinguishing shared scientific questions from individualized issues while complying with applicable disclosure requirements and admissibility standards.
Is an initial management conference mandatory under Rule 16.1?
No. Rule 16.1 states that the court should schedule a conference, but the Committee Notes clarify that it is not mandatory in every MDL.
Does Rule 16.1 establish separate expert disclosure deadlines?
No. Rule 26 and applicable court orders govern expert disclosures. An MDL court may set separate deadlines for common and individualized expert issues.
Can an MDL court address general causation before individual causation?
Yes. When appropriate, the court may structure discovery and motion practice to address common general-causation questions before individualized causation issues. The sequence depends on the claims, defenses, available evidence, and management needs of the proceeding.
Is expert testimony admitted in one MDL action automatically admissible in related actions?
No. Coordinated proceedings do not automatically make an expert opinion admissible in every related action. Rule 702 and other applicable evidentiary requirements continue to govern, and case-specific differences may affect the relevance or reliability of proposed testimony.
Does Rule 16.1 govern expert evidence in state court mass tort litigation?
No. Rule 16.1 directly addresses federal multidistrict litigation transferred under 28 U.S.C. § 1407. State court proceedings follow their applicable procedural and evidentiary rules, although courts may use similar case management approaches.
Rule 16.1(b)(2)(A) addresses whether leadership counsel should be appointed and, if so, how leadership should be structured. Appointment is not mandatory in every MDL.
When appointed, leadership counsel may coordinate common discovery and other pretrial activities within the authority granted by court orders. Responsibilities may include organizing scientific document production, expert depositions, and proposals for common evidentiary proceedings.
The Committee Notes emphasize communication with nonleadership counsel and opportunities for those attorneys to express their views to the court. Coordination must also account for counsel's continuing responsibilities to their clients.
Rule 16.1 supports early discussion of common factual issues, discovery difficulties, and significant pretrial motions without establishing separate expert-discovery requirements.
Rule 16.1(b)(3)(G) calls for the parties' initial views on the principal factual and legal issues likely to arise.
In litigation involving specialized evidence, these issues may include:
Pharmaceutical litigation: Clinical studies, epidemiological evidence, pharmacological mechanisms, and general causation.
Product liability litigation: Common product designs, manufacturing records, testing procedures, and alleged failure mechanisms.
Environmental litigation: Contaminant characteristics, sampling data, exposure pathways, and potential health risks.
Medical device litigation: Device design, engineering evaluations, clinical evidence, and reported complications.
Qualified experts may review relevant records, assess scientific methods, conduct appropriate testing, or explain technical findings.
The appropriate scope of analysis depends on the claims, defenses, and available evidence.
Rule 16.1(b)(3)(C) identifies discovery, including anticipated difficulties, as a subject for the parties' initial report.
A transferee court may use this information to develop discovery procedures suited to the litigation.
Depending on the circumstances, expert-related discovery may involve:
Coordinated production of scientific datasets and technical records.
Procedures for inspecting products or testing physical evidence.
Scheduling expert reports, depositions, and related discovery.
Sequencing discovery concerning common and individual issues.
Addressing confidentiality, privilege, and proportionality concerns.
These measures are discretionary, not required in every MDL.
In an MDL, expert evidence may address issues shared across multiple actions, but coordinated discovery does not eliminate the need for case-specific analysis.
In litigation involving an allegedly harmful pharmaceutical product, epidemiologists, pharmacologists, or toxicologists may evaluate whether the available scientific evidence supports an opinion that exposure to the product, under conditions relevant to the claims, is capable of causing a particular injury or condition.
This analysis concerns general causation. Depending on the substance and alleged injury, relevant considerations may include exposure levels, duration, and the available scientific evidence. Whether the exposure actually caused a particular claimant's injury is a separate question of specific causation.
In product liability litigation, common expert analysis might instead examine design specifications, materials, manufacturing processes, or alleged failure mechanisms.
Case-specific analysis addresses facts relevant to an individual action.
Depending on the dispute, a qualified expert may evaluate:
Individual exposure history and estimated exposure levels.
Medical records and diagnostic findings.
Alternative explanations for an alleged injury.
The circumstances surrounding a particular product failure.
Individual economic losses or other damages requiring specialized assessment.
Evidence that a substance can cause a particular condition does not, by itself, establish that it caused an individual claimant's condition.
The expert's methodology must fit the question being examined and the available facts.
Expert disclosures in federal MDL proceedings remain governed by Rule 26 and applicable court orders, not by separate disclosure requirements under Rule 16.1.
Under Rule 26(a)(2), parties generally must identify witnesses they may use at trial to present expert testimony.
Unless otherwise stipulated or ordered, Rule 26(a)(2)(B) requires a written report prepared and signed by each expert retained or specially employed to provide expert testimony and each employee whose duties regularly involve giving expert testimony.
The report must contain:
A complete statement of the expert's opinions and their bases and reasons.
The facts or data considered in forming those opinions.
Exhibits used to summarize or support the opinions.
The expert's qualifications, including publications authored during the preceding 10 years.
A list of cases in which the expert testified at trial or by deposition during the preceding four years.
A statement of compensation for the study and testimony.
Unless otherwise stipulated or ordered, Rule 26(a)(2)(C) requires summary disclosures for witnesses identified under Rule 26(a)(2)(A) who are not required to provide written reports.
Rule 26(a)(2)(D) requires expert disclosures at the times and in the sequence ordered by the court, with default deadlines applying when no relevant stipulation or court order controls.
In an MDL, the court may establish separate schedules for common and individualized expert work, including general-causation discovery before certain case-specific discovery when appropriate.
Rule 26(b)(4)(B) protects drafts of reports and disclosures required under Rule 26(a)(2), regardless of their recorded form.
Rule 26(b)(4)(C) generally protects communications between a party's attorney and an expert required to provide a written report. Exceptions apply to communications concerning expert compensation, facts or data provided by counsel that the expert considered, and assumptions provided by counsel that the expert relied on in forming an opinion.
Under Rule 26(b)(4)(D), discovery of facts known or opinions held by certain experts retained solely for trial preparation and not expected to testify is generally restricted, subject to specified exceptions, including a showing of exceptional circumstances.
Federal Rule of Evidence 702 continues to govern expert testimony admissibility in federal MDL proceedings. Rule 16.1 does not create a different standard.
Separately, Rule 16(c)(2)(C) and (D) allow courts to address evidentiary admissibility and limits on expert testimony during pretrial management.
Under Rule 702, the proponent must show that it is more likely than not that the rule's requirements are met.
When expert testimony is challenged, the court considers whether:
The expert is qualified by knowledge, skill, experience, training, or education.
The expert's specialized knowledge will assist the trier of fact.
The testimony is based on sufficient facts or data.
The testimony results from reliable principles and methods.
The opinion reflects a reliable application of those principles and methods to the facts of the case.
The 2023 amendment to Rule 702 clarified the applicable burden and emphasized the court's responsibility to evaluate the reliability of the expert's methodology and its application.
Rule 16.1(b)(3)(D) identifies likely pretrial motions as a subject for the parties' initial report.
When multiple actions share a scientific question, the transferee court may coordinate briefing or discovery related to Rule 702 challenges, such as disputes over an epidemiological expert's general-causation methodology.
Other challenges may depend on an expert's analysis of an individual claimant's circumstances.
Coordinated proceedings do not make an opinion automatically admissible in every related case. Courts must still apply Rule 702 to the testimony offered.
In Engilis v. Monsanto Co., 151 F.4th 1040 (9th Cir. 2025), an appeal arising from the Roundup MDL, the Ninth Circuit affirmed the exclusion of a specific-causation opinion based on an unreliable differential-etiology analysis. The expert had failed to provide a sufficiently reliable basis for ruling out obesity as a potential cause of the plaintiff's cancer.
The decision illustrates that case-specific causation opinions remain subject to Rule 702's reliability requirements even when the underlying litigation involves shared scientific issues.
Bellwether proceedings may help parties and courts evaluate recurring issues through selected actions, but Rule 16.1 does not require bellwether trials.
Bellwether trials must comply with applicable jurisdictional and procedural requirements. These include limits on a transferee court's authority to try cases transferred under 28 U.S.C. § 1407.
In Lexecon Inc. v. Milberg Weiss Bershad Hynes & Lerach, 523 U.S. 26 (1998), the Supreme Court held that an MDL transferee court could not use 28 U.S.C. § 1404(a) to assign a transferred action to itself for trial.
Under 28 U.S.C. § 1407(a), transferred actions that have not been terminated generally must be remanded by the Judicial Panel on Multidistrict Litigation to their originating districts at or before the conclusion of coordinated pretrial proceedings.
A valid waiver of an applicable Lexecon objection may permit a transferred action to be tried in the transferee district. Directly filed actions raise separate jurisdictional and venue considerations that depend on the circumstances and applicable orders.
In In re DePuy Orthopaedics, Inc., 870 F.3d 345 (5th Cir. 2017), a majority of the Fifth Circuit panel concluded that the MDL court erred in finding a broad waiver of the defendants' Lexecon objections. A different majority nevertheless denied the petition for a writ of mandamus because the petitioners had not established that they lacked another adequate means of obtaining relief.
Attorneys planning bellwether trials should therefore examine the filing or transfer history of the selected actions, applicable venue requirements, the scope of any waiver, and relevant case management orders.
The Rule 16.1 Committee Notes identify bellwether trials as one activity leadership counsel may help coordinate.
In selected cases, a product engineering expert may examine a shared design issue while another expert evaluates evidence concerning an individual claimant's alleged injury.
Findings in selected bellwether cases do not automatically determine the outcomes of other actions. Any broader legal effect depends on the applicable law and procedural circumstances.
Attorneys preparing for Rule 16.1 proceedings should focus on several practical considerations:
Identify common and individual issues: Distinguish shared technical questions from matters requiring case-specific analysis.
Assess evidence availability: Identify relevant scientific records, technical documents, testing materials, and preservation needs.
Evaluate expert methodologies: Consider the relevant professional disciplines, analytical methods, and potential admissibility disputes.
Plan discovery sequences: Determine whether experts need information from earlier discovery, consistent with Rule 26 and applicable court orders.
Monitor compliance: Track disclosure, supplementation, and discovery deadlines as MDL orders evolve.
Under Rule 37(c)(1), a party that fails to disclose information or identify a witness as required by Rule 26(a) or 26(e) generally cannot use that information or witness on a motion, at a hearing, or at trial unless the failure was substantially justified or harmless.
On motion and after an opportunity to be heard, the court may also impose specified sanctions instead of or in addition to exclusion, including reasonable expenses and attorney's fees caused by the failure.
Federal Rule of Civil Procedure 16.1 provides a flexible framework for early MDL management. Its procedures can help courts and parties identify common disputes, plan discovery, and coordinate expert-related pretrial activities.
Effective expert evidence management requires distinguishing shared scientific questions from individualized issues while complying with applicable disclosure requirements and admissibility standards.
Is an initial management conference mandatory under Rule 16.1?
No. Rule 16.1 states that the court should schedule a conference, but the Committee Notes clarify that it is not mandatory in every MDL.
Does Rule 16.1 establish separate expert disclosure deadlines?
No. Rule 26 and applicable court orders govern expert disclosures. An MDL court may set separate deadlines for common and individualized expert issues.
Can an MDL court address general causation before individual causation?
Yes. When appropriate, the court may structure discovery and motion practice to address common general-causation questions before individualized causation issues. The sequence depends on the claims, defenses, available evidence, and management needs of the proceeding.
Is expert testimony admitted in one MDL action automatically admissible in related actions?
No. Coordinated proceedings do not automatically make an expert opinion admissible in every related action. Rule 702 and other applicable evidentiary requirements continue to govern, and case-specific differences may affect the relevance or reliability of proposed testimony.
Does Rule 16.1 govern expert evidence in state court mass tort litigation?
No. Rule 16.1 directly addresses federal multidistrict litigation transferred under 28 U.S.C. § 1407. State court proceedings follow their applicable procedural and evidentiary rules, although courts may use similar case management approaches.
Federal Rules of Civil Procedure
Federal Rules of Civil Procedure